Highlights

  • Second quarter revenue rose 18% to $21.7 million, with an 81.9% gross margin and a net loss of $7.7 million.
  • Operating expenses fell 6% to $24.6 million, and the net loss per share improved to $0.25 from $0.38.
  • Management disclosed substantial doubt about going concern, citing debt repayment obligations, recurring losses and historical negative cash flows.
  • A ten-year BARDA agreement worth up to $25.5 million will keep RECELL supplied for burn mass casualty incidents.

AVITA Medical (NASDAQ:RCEL) shares were trading near their 52-week high at USD 14.87 on October 21, 2026, up 7.75%. The wound care company signed a $60 million credit facility in January, entered a ten-year BARDA agreement in April, and filed its second quarter 2026 report on August 6, which included going concern language alongside 18% revenue growth.

Based in Valencia, California, AVITA Medical is a Delaware corporation that calls itself a therapeutic acute wound care company. Its lead product is the RECELL autologous cell harvesting system, which creates Spray-On Skin from a patient's own cells and is FDA-approved for thermal burns and full-thickness skin defects, including the RECELL GO and RECELL GO mini versions. It also sells Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix, under exclusive agreements. Its CDIs are also quoted on the ASX, and its fiscal year ends December 31.

Revenue Up 18% With a Narrower Loss

Total revenue for the quarter ended June 30, 2026 was $21.7 million, up from $18.4 million a year earlier. Management credited Cohealyx, RECELL GO mini and a normalization of RECELL use after Medicare contractor reimbursement delays, which eased once all seven contractors had published rates by March 2026.

Gross profit rose 19% to $17.8 million, a margin of 81.9% versus 81.2%. Operating expenses fell 6% to $24.6 million, with sales and marketing down 5% to $13.6 million. The operating loss narrowed to $6.9 million from $11.1 million, and the net loss was $7.7 million, or $0.25 per share, against $9.9 million, or $0.38.

For the six months, revenue was $41.0 million, up 11%, and the net loss was $18.3 million versus $23.8 million. Operating cash outflow was $13.6 million, down from $20.5 million.

Going Concern, Credit Facility and New Agreements

The filing states that management found substantial doubt about the company's ability to continue as a going concern over the next twelve months, due to debt repayment obligations, recurring losses and historical negative cash flows. The accumulated deficit was $426.7 million, and cash, cash equivalents and marketable securities totaled $11.1 million at June 30. Because of that conclusion, the long-term portion of the credit facility is classified as a current liability. Management said it may need additional liquidity and is evaluating options, including drawing the additional $10 million commitment or raising equity, with no assurance either will be available.

The five-year Perceptive facility, signed January 13, provides up to $60 million, of which $50 million was drawn at closing. Net proceeds after repaying prior debt and fees were about $6.0 million. Revenue covenants include $73.0 million for the year ending December 31, 2026, and AVITA was in compliance at June 30. The lender received a warrant for 650,000 shares, issued June 8.

The BARDA agreement, dated April 6, has a potential value of up to $25.5 million and includes about $4.0 million of access and maintenance fees. In April, interim Cohealyx data showed time to autografting readiness of 13.6 days versus a 33.2-day literature benchmark. On August 5, a global amendment with Stedical raised AVITA's PermeaDerm revenue share, added a right of first offer on expanded territories for a $500,000 fee, and set 2026 minimum revenue-sharing payments of $1.0 million.

Outlook and Reimbursement Milestones

The 10-Q contains no numerical revenue guidance. Management's stated objectives include deeper RECELL use in about 200 U.S. burn and trauma centers, broader Cohealyx and RECELL GO mini adoption, and distributor-led international expansion upon regulatory approvals.

In July 2026, CMS proposed 2027 payment rules that include a new Category I CPT code family effective January 1, 2027. If finalized, physician reimbursement would move from contractor pricing to a national fee schedule, and final rules are expected later this year. These are company statements about expected events, not guarantees.